Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic LeukemiasGlobeNewsWire • 12/09/19
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceGlobeNewsWire • 09/23/19
Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid TumorsGlobeNewsWire • 09/09/19
Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference GlobeNewsWire • 09/04/19